Inhaled colistin following lung transplantation in colonised cystic fibrosis patients.

Abstract

Respiratory tract infections due to viral, bacterial or even fungal pathogens are common after lung transplantation [1]. Previous studies demonstrated increased hospitalisation rates and a greater risk of chronic lung allograft dysfunction in colonised patients with cystic fibrosis (CF) [2]. Positive effects of inhaled antibiotics have been demonstrated for pneumonia in non-transplant patients with improvements of lung function, hospitalisation rates and need for i.v. antibiotics [3, 4]. Inhaled colistin is known to provide high drug concentrations in sputum while low systemic concentrations occur and treatment is well tolerated [5]. Here, the impact of inhaled colistin, both in reducing bacterial load in previously colonised patients and as a preventive therapy in non-colonised CF patients, after lung transplantation, was studied in a retrospective single-centre study (Hanover Medical School, Hanover, Germany).

DOI: 10.1183/09031936.00201012

1 Figure or Table

Cite this paper

@article{Suhling2013InhaledCF, title={Inhaled colistin following lung transplantation in colonised cystic fibrosis patients.}, author={Hendrik Suhling and Jessica Rademacher and Mark W. Greer and Axel Haverich and G. Warnecke and Jens Gottlieb and Tobias Welte}, journal={The European respiratory journal}, year={2013}, volume={42 2}, pages={542-4} }